Impact Biomedical (IBO) Receivables - Other (2023)
Impact Biomedical's (IBO) quarterly Receivables - Other came in at $128000.0 in Q4 2023, up 36.17% quarter-over-quarter from $94000.0 in Q2 2023.
Powered by 
Analysis
Impact Biomedical (IBO) Receivables - Other (2023) Analysis & Trends
Impact Biomedical (IBO) has reported Receivables - Other for 1 consecutive years, with $128000.0 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Receivables - Other changed N/A year-over-year to $128000.0; the trailing twelve-month figure through Dec 2023 stood at $128000.0 (changed N/A YoY), and the FY2024 full-year result was -$128000.0, down 200.0% from the prior year.
- Receivables - Other improved to $128000.0 in Q4 2023 per IBO's latest filing, from $94000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $128000.0 in Q4 2023 and bottomed at $94000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 |